Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

AZD 9750 is a proteolysis-targeting chimera (PROTAC) composed of an androgen receptor ligand and a lenalidomide derivative.1 It induces the degradation of wild-type androgen receptor (AR) and drug-resistant mutant AR containing a leucine-to-histidine substitution at position 702 (ARL702H) with half-maximal degradation concentration (DC50) values of 10 and 12 nM, respectively. AZD 9750 (30 mg/kg) decreases tumor volume in a wild-type AR-expressing patient-derived xenograft (PDX) mouse model of prostate cancer.
WARNING This product is not for human or veterinary use.
1. Discovery of AZD9750, an orally bioavailable androgen receptor degrader for the treatment of prostate cancer. J. Med. Chem. 69(3), 3209-3232 (2026).